Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ribocytokine IL-7 BNT152

A formulation consisting of lipid nanoparticles (LNPs) encapsulating nucleoside-modified messenger RNA (mRNA) encoding the endogenous cytokine interleukin-7 (IL-7), with potential immunostimulating activity. Upon administration, ribocytokine IL-7 BNT152 is taken up by cells and the expressed IL-7 targets and binds to the IL-7 receptor (IL7R). The binding of IL-7 to IL7R activates IL7/IL7R-mediated signaling, which activates B and T lymphocytes, may improve immune recovery and activation, and may enhance anti-tumor immune responses.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	human interleukin-7 mRNA-encoded BNT152
Code name:	BNT 152 BNT-152 BNT152

ribocytokine IL-7 BNT152

Search NCI's Drug Dictionary